Metastatic colorectal cancer (mCRC) is characterized by molecular heterogeneity and the development of adaptive resistance to systemic therapies. Biomarkers have become central to understanding resistance biology and guiding treatment selection, spanning established genomic alterations, circulating tumor DNA (ctDNA)-ba...
C. Eslinger, D. Ahn, Z. Jin et al.· Future Oncology· 0 citations
Pancreatic cancer is associated with high morbidity and mortality. Gemcitabine plus nab-paclitaxel (GA), along with FOLFIRINOX and NALIRIFOX, is a standard first-line treatment for advanced/metastatic pancreatic ductal adenocarcinoma (mPDAC). However, the standard GA schedule (days 1, 8, and 15 of a 28-day cycle)...
C. Hoyek, C. Eslinger, Angelo Pirozzi et al.· BMC Cancer· 0 citations
ABSTRACT Introduction Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy in which activating KRAS mutations, present in more than 90% of tumors, constitute the principal oncogenic driver. Advances in structural biology have enabled the pharmacologic targeting of KRAS, a protein historically regarded as...
Joanna Kreidi, C. Hoyek, C. Eslinger et al.· Expert Opinion on Biological...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.